The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2016 | Why it is important to involve children and adolescents in treatment decision-making
Imelda Coyne, PhD from Trinity College Dublin, Dublin, Ireland discusses the importance of encouraging the participation of children and adolescents in shared treatment decision-making. Whilst at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain, Prof. Coyne compares the attitudes of children versus adolescents towards involvement in their treatment. Younger children tend to be more willing to rely on the judgment of parents or healthcare professions while adolescents wish to be more informed and to be able to contribute to decisions made. Whether a decision is regarded big or small, it holds as much importance to the patient and this should not be overlooked when involving children and adolescents in decisions regarding their treatment and care.
